Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

25.06.24 00:00 Uhr

Werte in diesem Artikel
Aktien

640,00 JPY -16,00 JPY -2,44%

448,80 EUR -1,40 EUR -0,31%

Indizes

PKT PKT

19.522,6 PKT -182,5 PKT -0,93%

17.726,9 PKT -144,3 PKT -0,81%

5.505,0 PKT -39,6 PKT -0,71%

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $474.95, marking a +1.33% move from the previous day. This change outpaced the S&P 500's 0.31% loss on the day. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, lost 1.09%.Prior to today's trading, shares of the drugmaker had gained 2.57% over the past month. This has outpaced the Medical sector's gain of 0.61% and lagged the S&P 500's gain of 2.73% in that time.The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to investors. The company's earnings per share (EPS) are projected to be $4.10, reflecting a 5.4% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.63 billion, indicating a 5.3% increase compared to the same quarter of the previous year.Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.13 per share and revenue of $10.72 billion. These totals would mark changes of +12.48% and +8.6%, respectively, from last year.Investors should also take note of any recent adjustments to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.22% increase. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 27.36. This denotes a premium relative to the industry's average Forward P/E of 24.It's also important to note that VRTX currently trades at a PEG ratio of 2.14. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.94 as of yesterday's close.The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.Free Report: 5 “Whisper” Stocks Poised to Stun Wall Street Analysts may be seriously underestimating these stocks. When they announce earnings, they could immediately jump +10-20%.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf note

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf note

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Vertex Pharmaceuticals Inc.

Analysen zu Vertex Pharmaceuticals Inc.

DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
26.10.2018Vertex Pharmaceuticals BuyH.C. Wainwright & Co.
01.10.2018Vertex Pharmaceuticals OverweightCantor Fitzgerald
07.08.2018Vertex Pharmaceuticals BuyStifel, Nicolaus & Co., Inc.
05.03.2018Vertex Pharmaceuticals BuyMaxim Group
01.02.2018Vertex Pharmaceuticals OverweightBarclays Capital
DatumRatingAnalyst
01.08.2019Vertex Pharmaceuticals HoldNeedham & Company, LLC
06.02.2019Vertex Pharmaceuticals HoldMaxim Group
24.10.2016Vertex Pharmaceuticals NeutralH.C. Wainwright & Co.
29.01.2015Vertex Pharmaceuticals HoldMaxim Group
29.01.2015Vertex Pharmaceuticals HoldNeedham & Company, LLC
DatumRatingAnalyst
14.12.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
05.11.2012Vertex Pharmaceuticals sellGoldman Sachs Group Inc.
04.01.2008Vertex Pharmaceuticals DowngradeWachovia Sec
14.12.2006Vertex Pharmaceuticals DowngradeBanc of America Sec.
22.11.2005Update Vertex Pharmaceuticals Inc.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vertex Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"